Rentschler Biotechnologie and Rentschler Fill Solutions Announce Strategic Partnership

13-Jun-2017 - Germany

Rentschler Biotechnologie GmbH and Rentschler Fill Solutions GmbH announced a strategic partnership to provide new fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biotechnologie’s clients. Under the terms of the agreement, Rentschler Fill Solutions will prospectively serve as the exclusive partner for the fill and finish services of Rentschler Biotechnologie’s manufacturing projects. Rentschler Fill Solutions is owned by the Rentschler family and will begin operations in mid-2018. In addition to servicing Rentschler Biotechnologie’s clients, Rentschler Fill Solutions will offer its fill and finish services on a clinical as well as commercial scale to its own client base.

“Based on the maturity of the biotech industry and demand for new drugs in growing international markets, we are also seeing more and more demand not only in terms of manufacturing for clinical studies but for commercial-scale manufacturing and market supply. In order to manage the expected growth and provide clients with new, scalable, state-of-the art technologies and facilities, this new partnership with Rentschler Fill Solutions, will allow us to meet today´s and the future needs of our clients,” Dr Frank Mathias, CEO of Rentschler Biotechnologie, commented. “Rentschler Biotechnologie is continually seeking and improving ways to help clients achieve their goals, all along the value chain – from cell line development through finished products. This partnership also supports our recent strategic alliance with Leukocare, as improved formulation strategies will contribute to the quality of the fill and finish process. Both partnerships will enable us to serve our clients as they grow.”

“Our state-of-the-art fill and finish facility has been designed to deliver high quality products and reliable services to our clients. As an independent specialist for the aseptic filling of liquid and lyophilized biopharmaceuticals, we aim to manage the specific filling requirements of a wide range of biopharmaceutical companies from clinical studies through market supply,” added Reinhold Elsaesser, General Manager of Rentschler Fill Solutions. “We very much look forward to working with Rentschler Biotechnologie to address clinical and market needs in terms of capacity, scalability, time to market, purity and safety. The clients of both companies will benefit from reliable one-stop solutions and a fast time to market based on our common commitment to quality and aligned processes.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances